Knowledge domain and evolutionary trends of P2Y receptors in cardiovascular diseases: a bibliometric and altmetric analysis
P2Y receptor research has transformed from a singular antithrombotic focus into a multidimensional regulatory network. While P2Y<sub>12</sub> antagonists remain clinically dominant, emerging frontiers focus on "de-escalation" strategies, immune-inflammation, and myocardial regeneration. Future progress relies on systematic evaluation of subtype selectivity and novel delivery systems, positioning P2Y receptor modulation as a promising avenue for precision cardiovascular medicine.
Authors
- Xuezhang Chen (ORCID: https://orcid.org/0000-0002-4780-5274)
- Liming Lu (ORCID: https://orcid.org/0000-0001-7821-4699)
- Ju Chen (ORCID: https://orcid.org/0009-0005-9731-3365)
- Mengyu Yang (ORCID: https://orcid.org/0009-0005-3302-7095)
- Jingchun Zeng (ORCID: https://orcid.org/0009-0009-4815-3982)
- Shiyin Lie
- Jingjing Li
- Xuanrui Chen
- Zhiqiang Zhang
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Baokang Hospital Affiliated to Tianjin University of Traditional Chinese Medicine (CN)
- Foshan Hospital of TCM (CN)
- First Affiliated Hospital of Guangzhou University of Chinese Medicine (CN)
- Zhongshan Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-20
- DOI
- https://doi.org/10.3389/fphar.2025.1731397
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Guangzhou University of Chinese Medicine
- Guangzhou University